TNFRSF17 and Hemiparesis: Anti-BCMA drugs, while associated with clinically significant incidences of ICANS, have also been linked to atypical neurotoxic events that appear distinct from ICANS in several clinical studies, including tremor and hemiparesis (32, 42).